Literature DB >> 16652279

Lopinavir-ritonavir: effects on endothelial cell function in healthy subjects.

Jessica R Grubb1, André Dejam, Jocelyn Voell, William C Blackwelder, Peter A Sklar, Joseph A Kovacs, Richard O Cannon, Henry Masur, Mark T Gladwin.   

Abstract

To differentiate between the effects that antiretroviral drugs have on the endothelium and the secondary effects that they have on immune function, viral load, and dyslipidemia, 6 non-human immunodeficiency virus-infected human subjects were treated with lopinavir-ritonavir for 1 month and, on the basis of forearm blood flow, the treatment's effects on endothelial cell function were measured. Surprisingly, after exposure to lopinavir-ritonavir, absolute forearm blood-flow responses to the endothelium-dependent vasodilator, acetylcholine, increased significantly (P=.03), and forearm blood flow decreased to a greater extent during specific inhibition of NO synthase by N(G)-monomethyl-L-arginine. Thus, in this small cohort of subjects, short-term treatment with lopinavir-ritonavir does not appear to directly promote endothelial cell dysfunction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16652279     DOI: 10.1086/503807

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  Proteinuria and endothelial dysfunction in stable HIV-infected patients. A pilot study.

Authors:  Samir K Gupta; Kieren J Mather; Rajiv Agarwal; Chandan K Saha; Robert V Considine; Michael P Dubé
Journal:  J Acquir Immune Defic Syndr       Date:  2007-08-15       Impact factor: 3.731

2.  Coronary and peripheral endothelial function in HIV patients studied with positron emission tomography and flow-mediated dilation: relation to hypercholesterolemia.

Authors:  Anne-Mette Lebech; Ulrik Sloth Kristoffersen; Niels Wiinberg; Kristian Kofoed; Ove Andersen; Birger Hesse; Claus Leth Petersen; Jan Gerstoft; Andreas Kjaer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-07-26       Impact factor: 9.236

3.  Relationship of body composition, metabolic status, antiretroviral use, and HIV disease factors to endothelial dysfunction in HIV-infected subjects.

Authors:  Michael P Dubé; Changyu Shen; Kieren J Mather; Jeff Waltz; Martha Greenwald; Samir K Gupta
Journal:  AIDS Res Hum Retroviruses       Date:  2010-08       Impact factor: 2.205

4.  Endothelial, inflammatory, coagulation, metabolic effects and safety of etravirine in HIV-uninfected volunteers.

Authors:  Samir K Gupta; Deming Mi; Ziyue Liu; Chandan Saha
Journal:  AIDS Patient Care STDS       Date:  2011-04-06       Impact factor: 5.078

5.  Combination antiretroviral therapy modulates the blood oxygen level-dependent amplitude in human immunodeficiency virus-seropositive patients.

Authors:  Beau M Ances; Anne C Roc; Marc Korczykowski; Ronald L Wolf; Dennis L Kolson
Journal:  J Neurovirol       Date:  2008-10       Impact factor: 2.643

6.  Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s.

Authors:  Francesca J Torriani; Lauren Komarow; Robert A Parker; Bruno R Cotter; Judith S Currier; Michael P Dubé; Carl J Fichtenbaum; Mariana Gerschenson; Carol K C Mitchell; Robert L Murphy; Kathleen Squires; James H Stein
Journal:  J Am Coll Cardiol       Date:  2008-08-12       Impact factor: 24.094

7.  Insulin resistance predicts endothelial dysfunction and cardiovascular risk in HIV-infected persons on long-term highly active antiretroviral therapy.

Authors:  Kristin E Mondy; Lisa de las Fuentes; Alan Waggoner; Nur F Onen; Coco S Bopp; Sherry Lassa-Claxton; William G Powderly; Victor Dávila-Román; Kevin E Yarasheski
Journal:  AIDS       Date:  2008-04-23       Impact factor: 4.177

Review 8.  The roles of HIV-1 proteins and antiretroviral drug therapy in HIV-1-associated endothelial dysfunction.

Authors:  Erik R Kline; Roy L Sutliff
Journal:  J Investig Med       Date:  2008-06       Impact factor: 2.895

9.  No impairment of endothelial function or insulin sensitivity with 4 weeks of the HIV protease inhibitors atazanavir or lopinavir-ritonavir in healthy subjects without HIV infection: a placebo-controlled trial.

Authors:  Michael P Dubé; Changyu Shen; Martha Greenwald; Kieren J Mather
Journal:  Clin Infect Dis       Date:  2008-08-15       Impact factor: 9.079

10.  Endothelial dysfunction, arterial stiffening, and intima-media thickening in large arteries from HIV-1 transgenic mice.

Authors:  Laura Hansen; Ivana Parker; Roy L Sutliff; Manu O Platt; Rudolph L Gleason
Journal:  Ann Biomed Eng       Date:  2012-11-22       Impact factor: 3.934

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.